Cargando…

Non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020)

Nucleosides and their derivatives are a well-known and well-described class of compounds with antiviral activity. Currently, in the era of the COVID-19 pandemic, scientists are also looking for compounds not related to nucleosides with antiviral properties. This review aims to provide an overview of...

Descripción completa

Detalles Bibliográficos
Autores principales: Denel-Bobrowska, Marta, Olejniczak, Agnieszka B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769541/
https://www.ncbi.nlm.nih.gov/pubmed/35085926
http://dx.doi.org/10.1016/j.ejmech.2022.114136
_version_ 1784635167622561792
author Denel-Bobrowska, Marta
Olejniczak, Agnieszka B.
author_facet Denel-Bobrowska, Marta
Olejniczak, Agnieszka B.
author_sort Denel-Bobrowska, Marta
collection PubMed
description Nucleosides and their derivatives are a well-known and well-described class of compounds with antiviral activity. Currently, in the era of the COVID-19 pandemic, scientists are also looking for compounds not related to nucleosides with antiviral properties. This review aims to provide an overview of selected synthetic antiviral agents not associated to nucleosides developed against human viruses and introduced to preclinical and clinical trials as well as drugs approved for antiviral therapy over the last 10 years. The article describes for the first time the wide classification of such antiviral drugs and drug candidates and briefly summarizes the biological target and clinical applications of the compounds. The described compounds are arranged according to the antiviral mechanism of action. Knowledge of the drug's activity toward specific molecular targets may be the key to researching new antiviral compounds and repositioning drugs already approved for clinical use. The paper also briefly discusses the future directions of antiviral therapy. The described examples of antiviral compounds can be helpful for further drug development.
format Online
Article
Text
id pubmed-8769541
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-87695412022-01-20 Non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020) Denel-Bobrowska, Marta Olejniczak, Agnieszka B. Eur J Med Chem Article Nucleosides and their derivatives are a well-known and well-described class of compounds with antiviral activity. Currently, in the era of the COVID-19 pandemic, scientists are also looking for compounds not related to nucleosides with antiviral properties. This review aims to provide an overview of selected synthetic antiviral agents not associated to nucleosides developed against human viruses and introduced to preclinical and clinical trials as well as drugs approved for antiviral therapy over the last 10 years. The article describes for the first time the wide classification of such antiviral drugs and drug candidates and briefly summarizes the biological target and clinical applications of the compounds. The described compounds are arranged according to the antiviral mechanism of action. Knowledge of the drug's activity toward specific molecular targets may be the key to researching new antiviral compounds and repositioning drugs already approved for clinical use. The paper also briefly discusses the future directions of antiviral therapy. The described examples of antiviral compounds can be helpful for further drug development. Elsevier Masson SAS. 2022-03-05 2022-01-19 /pmc/articles/PMC8769541/ /pubmed/35085926 http://dx.doi.org/10.1016/j.ejmech.2022.114136 Text en © 2022 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Denel-Bobrowska, Marta
Olejniczak, Agnieszka B.
Non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020)
title Non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020)
title_full Non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020)
title_fullStr Non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020)
title_full_unstemmed Non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020)
title_short Non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020)
title_sort non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769541/
https://www.ncbi.nlm.nih.gov/pubmed/35085926
http://dx.doi.org/10.1016/j.ejmech.2022.114136
work_keys_str_mv AT denelbobrowskamarta nonnucleosidestructuredcompoundswithantiviralactivitypast10years20102020
AT olejniczakagnieszkab nonnucleosidestructuredcompoundswithantiviralactivitypast10years20102020